NASDAQ:HRMY - Harmony Biosciences Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $53.25
  • Forecasted Upside: 34.47 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$39.60
▼ -0.16 (-0.40%)

This chart shows the closing price for HRMY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Harmony Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HRMY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HRMY

Analyst Price Target is $53.25
▲ +34.47% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Harmony Biosciences in the last 3 months. The average price target is $53.25, with a high forecast of $58.00 and a low forecast of $43.00. The average price target represents a 34.47% upside from the last price of $39.60.

This chart shows the closing price for HRMY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 investment analysts is to buy stock in Harmony Biosciences.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/17/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/15/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/14/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/14/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/12/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/10/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/9/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/9/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/30/2021OppenheimerInitiated CoverageOutperform$55.00High
11/3/2021Raymond JamesInitiated CoverageOutperform$58.00Medium
9/22/2021Needham & Company LLCInitiated CoverageBuy$57.00Medium
3/29/2021The Goldman Sachs GroupUpgradeNeutral ➝ Buy$41.00 ➝ $43.00High
9/14/2020Jefferies Financial GroupInitiated CoverageBuy$51.00High
9/14/2020Piper SandlerInitiated CoverageOverweight$61.00High
9/13/2020The Goldman Sachs GroupInitiated CoverageNeutral$43.00High
(Data available from 12/9/2016 forward)

News Sentiment Rating

1.48 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/13/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/12/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/12/2021
  • 4 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/11/2021
  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/10/2021
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/10/2021
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/9/2021
  • 13 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/9/2021

Current Sentiment

  • 13 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Harmony Biosciences logo
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy in the United States. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
Read More

Today's Range

Now: $39.60
Low: $39.06
High: $40.37

50 Day Range

MA: $39.38
Low: $34.09
High: $43.01

52 Week Range

Now: $39.60
Low: $25.09
High: $44.65

Volume

266,690 shs

Average Volume

294,869 shs

Market Capitalization

$2.32 billion

P/E Ratio

198.01

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Harmony Biosciences?

The following Wall Street analysts have issued stock ratings on Harmony Biosciences in the last year: Needham & Company LLC, Oppenheimer Holdings Inc., Raymond James, The Goldman Sachs Group, Inc., and Zacks Investment Research.
View the latest analyst ratings for HRMY.

What is the current price target for Harmony Biosciences?

4 Wall Street analysts have set twelve-month price targets for Harmony Biosciences in the last year. Their average twelve-month price target is $53.25, suggesting a possible upside of 34.5%. Raymond James has the highest price target set, predicting HRMY will reach $58.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $43.00 for Harmony Biosciences in the next year.
View the latest price targets for HRMY.

What is the current consensus analyst rating for Harmony Biosciences?

Harmony Biosciences currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe HRMY will outperform the market and that investors should add to their positions of Harmony Biosciences.
View the latest ratings for HRMY.

How do I contact Harmony Biosciences' investor relations team?

Harmony Biosciences' physical mailing address is 630 W GERMANTOWN PIKE SUITE 215, PLYMOUTH MEETING PA, 19462. The company's listed phone number is 484-539-9800 and its investor relations email address is [email protected] The official website for Harmony Biosciences is www.harmonybiosciences.com.